Person: YAZİCİ, SERKAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
YAZİCİ
First Name
SERKAN
Name
4 results
Search Results
Now showing 1 - 4 of 4
Publication Rates of skincare product and cosmetic procedure use in patients with acne vulgaris and the effective factors: A multicenter study with 1,755 patients(Wiley, 2022-06) Kayıran, Melek Aslan; Karadağ, Ayşe Serap; Alyamaç, Gökçen; Cemil, Bengü Çevirgen; Demirseren, Duriye Deniz; Demircan, Yuhanize Tas; Aksoy, Hasan; Kilic, Sevilay; Polat, Asude Kara; Yuksel, Esma Inan; Kalkan, Goknur; Aksac, Sema Elibuyuk; Kutlu, Omer; Kaksi, Sumeyye Altintas; Akturk, Aysun Sikar; Akbulut, Tugba Ozkok; Solak, Sezgi Sarikaya; Topal, Ilteris Oguz; Yazici, Serkan; Ozden, Hatice Kaya; Koska, Mahmut Can; Uzuncakmak, Tugba Kevser; Ataseven, Arzu; Işık, Begüm; Alpsoy, Erkan; YAZİCİ, SERKAN; Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıklar Anabilim Dalı; 0000-0001-6407-0962; AAH-2459-2021Background: Skincare products and cosmetic procedures are used as an adjunct or complementary to conventional drug therapy for acne vulgaris (AV). Objective: To evaluate the use of skincare products and the frequency of cosmetic procedures in AV treatment. Methods: A total of 1,755 patients with AV completed the survey prepared by the researchers and the Cardiff Acne Disability Index (CADI) questionnaire. The clinical findings and the Food and Drug Administration (FDA) severity scores were recorded by the dermatologists. Results: For AV, 66.7% of the patients stated that they used skincare products and 26.7% had undergone cosmetic procedures. The use of skincare products was statistically significantly higher in women (female: 74.5%, male: 57.7%, p < 0.0001); older people (users: 22 ± 7.6years, non-users: 21.2 ± 5.7 years, p < 0.0001); patients with a higher CADI score (users: 7 ± 3.7, non-users: 6.9 ± 4.3, p = 0.010); FDA severity score 2 and 3 (FDA-1: 58.1%; FDA-2: 72.4%, FDA-3: 73%, FDA-4: 67%, p < 0.0001); long-term disease (users: 57 ± 43 months; non-users: 47.7 ± 42.3 months, p < 0.0001); facial involvement (present: 70.2%, absent: 51.4%, p = 0.017); high income levels (users: 73.5%; non-users: 26.5%, p = 0.001); and graduate or post-graduate degrees (undergraduate≤%62.8, graduate≥%76.8, p < 0.0001). The rate of cosmetic procedures was higher in those with higher CADI scores (users: 7.8 ± 3.8; non-users: 7.1 ± 3.96, p < 0.0001); older patients (users: 22.7 ± 10.7 years; non-users: 21.3 ± 5 years, p < 0.0001); high school (25.6%); and graduate (28.9%) education (p = 0.043), those with lower disease severity (FDA-1: 31.1%; FDA-2: 28.5%, FDA-3: 27.1%, FDA-4: 20.4%, p = 0.022); smokers (smokers: 32.5%; non-smokers: 25.5%, p = 0.020), and those with AV in the family (present: 29.8%; absent: 24.2%, p = 0.009). The patients most frequently used cleansers (85.2%) as cosmetic products, and most commonly underwent skincare treatment (71%) as an interventional procedure. They mostly learned about such products and methods from the Internet, and 33.3% of the participants had undergone procedures performed by non-physicians. Conclusion: The patients generally choose skincare products as a result of their Internet search and sometimes have these procedures performed by non-physicians. Dermatologists should be aware of this situation and inform their patients about appropriate products and procedures.Publication Social media use in patients with acne vulgaris: What do patients expect from social media?(Wiley, 2021-06-01) Kayıran, Melek Aslan; Karadağ, Ayşe Serap; Alyamaç, Gökçen; Cemil, Bengü Çevirgen; Demirseren, Düriye Deniz; Aksoy, Hasan; Kılıç, Sevilay Oğuz; Demircan, Yuhanize Taş; Yüksel, Esma İnan; Kalkan, Göknur; Yaşar, Gülbin; Aktürk, Aysun Sıkar; Kutlu, Ömer; Kaksi, Sümeyye Altıntaş; Aksaç, Sema Elibüyük; Erdoğan, Hilal Kaya; Özden, Hatice Kaya; Solak, Sezgi Sarıkaya; Koska, Mahmut Can; Yazıcı, Serkan; YAZİCİ, SERKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıklar Anabilim Dalı.; AAH-2459-2021Background Acne vulgaris (AV) may affect external appearance and significantly deteriorate the quality of life of patients. Therefore, patients make various inquiries about their disease and seek treatment options.Aims To investigate the social media usage habits of patients with AV concerning their diseases, and their recommendations for dermatologists related to social media use.Methods A total of 1609 patients with AV completed the survey prepared by the authors and the Cardiff Acne Disability Index questionnaire. The Food and Drug Administration severity scores and clinical information of the patients were noted by their physicians.Results Of the 1,489 patients who stated that they used social media, 46.31% regularly and 28.77% sometimes referred to these sources to make inquiries about AV. Social media usage for AV was statistically significantly higher in women, participants with short term and severe disease, those with a moderate income level, and those using topical treatment and cosmetics. They mostly used Google (67%), Instagram (54%), and YouTube (49%). While 76% of the participants stated that they did not share what they saw on the Internet with their doctor. Of the respondents, 18.5% were trying to contact their dermatologists through the Internet, and 69.73% would prefer experts such as dermatologists to post-AV-related content.Conclusions Our study shows that patients frequently resort to social media to seek information about AV. In the changing digital world order, it is observed that there is a need for dermatologists to use social media more actively to share accurate information about AV.Publication The ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans(Assoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevo, 2021-01-01) Tanriverdi, Ozgur; Ozsen, Mine; ÖZŞEN, MİNE; Deligonul, Adem; DELİGÖNÜL, ADEM; Yazici, Serkan; YAZİCİ, SERKAN; Cetintas, Sibel Kahraman; Yalcinkaya, Ulviye; YALÇINKAYA, ÜLVİYE; Sahin, Ahmet Bilgehan; ŞAHİN, AHMET BİLGEHAN; Orhan, Sibel Oyucu; OYUCU ORHAN, SİBEL; Ocak, Birol; OCAK, BİROL; Evrensel, Turkkan; EVRENSEL, TÜRKKAN; Kahveci, Ramazan; KAHVECİ, RAMAZAN; Cubukcu, Erdem; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Plastik Cerrahi ve Estetik Anabilim Dalı.; 0000-0001-6407-0962; 0000-0002-5771-7649; 0000-0002-7846-0870; 0000-0002-0598-7284; 0000-0001-7537-1699; AAJ-8314-2021; AEC-2238-2022; AAM-4927-2020; M-2172-2015Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue sarcoma that originates from the dermis or subcutaneous tissue in the skin. While its prognosis is generally favorable, disease recurrence is relatively frequent. Since morbidity after repeated surgery may be significant, an optimized prediction of recurrence-free survival (RFS) has the potential to improve current management strategies. The purpose of this study was to investigate the prognostic value of the Ki-67 proliferation index with respect to RFS in patients with DFSP We retrospectively analyzed data from 45 patients with DFSP. We calculated the Ki-67 proliferation index as the percentage of immunostained nuclei among the total number of tumor cell nuclei regardless of the intensity of immunostaining. We constructed univariate and multivariate Cox proportional hazards regression models to identify predictors of RFS. Among the 45 patients included in the study, 8 developed local recurrences and 2 had lung metastases (median follow-up: 95.o months; range: 5.2-412.4 months). The RFS rates at 60, 120, and 240 months of follow-up were 83.8%, 76.2%, and 65.3%, respectively. The median Ki-67 proliferation index was 14%. Notably, we identified the Ki-67 proliferation index as the only independent predictor for RFS in multivariate Cox proportional hazards regression analysis (hazard ratio = 1.106, 95% confidence interval = 1.019-1.200, p = 0.016). In summary, our results highlight the potential usefulness of the Ki-67 proliferation index for facilitating the identification of patients with DFSP at a higher risk of developing disease recurrences.Publication Predictors of drug survival of biologic therapies in psoriasis patients (vol 45, pg 813, 2020)(Taylor & Francis, 2020-08-31) Zorlu, Özge; Başkan, Emel Bülbül; BÜLBÜL BAŞKAN, EMEL; Yazıcı, Serkan; YAZİCİ, SERKAN; Sığırlı, Deniz; SIĞIRLI, DENİZ; Budak, Ferah; BUDAK, FERAH; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; Aydoğan, Kenan; AYDOĞAN, KENAN; Cevhertas, Laçin; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim; 0000-0001-5555-130X; 0000-0001-6407-0962; 0000-0001-7625-9148; 0000-0002-0193-1128; 0000-0003-2287-3569; AAH-1388-2021; AAH-6216-2021; AAA-7472-2021; F-4657-2014; IZP-9398-2023; AAH-2459-2021